Exact Science, ALTUS2021-01, at Risk for Hepatocellular Ca (HCC), Multi-Target Test Oncoguard

What is the Purpose of this Study?

Primary Objective: Assess overall sensitivity and specificity of Oncoguard Liver for hepatocellular cancer (HCC) detection in a surveillance population. Secondary Objective(s): Assess performance of Oncoguard Liver in confirmed HCC and non-HCC population. Assess early-stage sensitivity of Oncoguard Liver for HCC detection in a surveillance population.


Eligibility

  • * All Subjects:
  • 1. Subject is 18 years of age or older
  • 2. Subject understands the study procedures and is able to provide informed consent to participate in the study and authorization for release of data, including personal health data, to the study investigator and sponsor
Show more

Where can I participate?

CS Cancer at Cedars-Sinai Medical Center

More about this Clinical Trial

What is the full name of this clinical trial?

ALTUS2021-01: ALTUS: Performance of a Multi-Target Hepatocellular Carcinoma Test in Subjects with Increased Risk

Study Details
Disease Type/Condition

Gastrointestinal Cancer, Liver Cancer

Principal Investigator

Yang, Ju Dong

Co-Investigators

Walid Ayoub

Age Group

Adult

Phase

N/A (Cancer Control)

IRB Number

STUDY00001693

ClinicalTrials.gov ID

NCT03628651

Key Eligibility
ClinicalTrials.gov

How do I learn more about this study?
Email
clinicaltrials@cshs.org
Study Detail
Disease Type/Condition

Gastrointestinal Cancer, Liver Cancer

Principal Investigator

Yang, Ju Dong

Age Group

Adult

Phase

N/A (Cancer Control)

IRB Number

ALTUS2021-01

ClinicalTrials.gov ID

NCT03628651

Key Eligibility
ClinicalTrials.gov

Contact
Email
clinicaltrials@cshs.org